Urigen Pharmacueticals
Stage
Unattributed | AliveTotal Raised
$100KLast Raised
$100K | 16 yrs agoAbout Urigen Pharmacueticals
Urigen specializes in the design and commercialization of innovative products for patients with urological ailments. The company develops products for amelioration of Painful Bladder Syndrome (PBS), Urethritis, Nocturia and Over Active Bladder (OAB).
Missing: Urigen Pharmacueticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Urigen Pharmacueticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Urigen Pharmacueticals Patents
Urigen Pharmacueticals has filed 4 patents.
The 3 most popular patent topics include:
- G protein coupled receptors
- Syndromes
- Urinary bladder disorders
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
2/27/2018 | 2/23/2021 | G protein coupled receptors, Syndromes, Urinary bladder disorders, Dosage forms, Gynaecology | Grant |
Application Date | 2/27/2018 |
|---|---|
Grant Date | 2/23/2021 |
Title | |
Related Topics | G protein coupled receptors, Syndromes, Urinary bladder disorders, Dosage forms, Gynaecology |
Status | Grant |
Latest Urigen Pharmacueticals News
Jul 30, 2018
06:45 EDT 30 Jul 2018 | BioPortfolio Reports Summary Urigen Pharmaceuticals Inc Urigen is a specialty pharmaceutical company that develops and commercializes therapeutic products for urological disorders. The company focuses on developing innovative products for amelioration of urethritis , painful bladder syndrome PBS, nocturia and over active bladder OAB . Its pipeline includes its flagship candidate, URG101, being developed for the painful bladder syndrome/interstitial cystitis. The company licensed URG101, is a proprietary combination therapy for the relief of pain of bladder. Its other product candidate, URG501, is in preclinical development. Urigen is headquartered in North Brunswick, New Jersey, the US. Urigen Pharmaceuticals Inc Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News
Urigen Pharmacueticals Frequently Asked Questions (FAQ)
Where is Urigen Pharmacueticals's headquarters?
Urigen Pharmacueticals's headquarters is located at 675 US Highway 1, North Brunswick.
What is Urigen Pharmacueticals's latest funding round?
Urigen Pharmacueticals's latest funding round is Unattributed.
How much did Urigen Pharmacueticals raise?
Urigen Pharmacueticals raised a total of $100K.
Who are the investors of Urigen Pharmacueticals?
Investors of Urigen Pharmacueticals include Kansas Technology Enterprise Corporation, Valentis, Aisling Capital and UCL Business.
Who are Urigen Pharmacueticals's competitors?
Competitors of Urigen Pharmacueticals include Charleston Laboratories, Aegerion Pharmaceuticals, Alexza Pharmaceuticals, Ikaria, Auxilium Pharmaceuticals, TARIS Biomedical - LiRIS, Presidio Pharmaceuticals, SkinMedica, Nanomed Pharmaceuticals, Prism Pharmaceuticals and 13 more.
Compare Urigen Pharmacueticals to Competitors
Slate currently markets Testopel in the United States. Testopel is an FDA-approved subcutaneous implantable testosterone pellet. Testopel is used for the treatment of testosterone deficiency in aging men as well as androgen deficiency caused by other conditions.
Wilmington Pharmaceuticals believes in fixing missed opportunities in established pharmaceutical products. With this product strategy, the company enjoys streamlined regulatory approval paths, relatively low R&D costs, and lower risks than traditional pharmaceutical product development programs. The company is currently completing the final clinical trial required for their initial product -- a fast dissolving version of a nausea and gastric distress product. This new product addresses proven market needs with improved delivery systems that are familiar to physicians and welcomed by patients. Wilmington Pharmaceuticals will begin work later this year on an improved version of a major pain drug.
Axcan is a specialty pharmaceutical company focused on the development and commercialization of drugs for diseases involving the digestive system.
Sirion Holdings is a specialty pharmaceutical company focused on ophthamology drugs
Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.
ThyroChek is the only available rapid test for elevated TSH approved by the FDA. It is a rapid, qualitative test for elevated TSH, thyroid stimulating hormone, a clinical indicator of hypothyroidism. Screening Devices Canada is producing products for the thyroid health market in the United States which is a market valued at $1.2B annually.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.